The sale transforms Surgery Partners into a pure-play short-stay surgical provider with lower leverage and a cleaner payor mix. Monitor Q3 2026 earnings for evidence of same-facility revenue growth acceleration and margin expansion from the streamlined portfolio.
Price Chart
Executive Summary
Surgery Partners completed the sale of its Idaho Falls facilities for $797M gross proceeds ($587M net), using proceeds primarily for debt paydown. The transaction reduces leverage by 30bps to ~4.1x, eliminates low-acuity service lines, and shifts the company to a pure-play short-stay surgical model. Updated FY2026 revenue guidance of $3.08B-$3.18B reflects the removal of Idaho Falls contributions for the remainder of the year.
Key Financial Metrics
Key Facts
- Sale of Idaho Falls facilities closed for $797M gross / $587M net cash proceeds
- Transaction valued at ~$1.15B; 7x LTM adjusted EBITDA multiple
- Leverage improves 30bps from 4.4x to ~4.1x under credit agreement
- Proceeds primarily used for debt paydown
- Updated FY2026 revenue guidance: $3.08B-$3.18B; Adjusted EBITDA at least $489M
- Pro forma (ex-Idaho Falls full year): revenue $2.60B-$2.67B; Adj. EBITDA at least $414M
- Medicaid payor mix reduced by 50% to under 2% of revenue; neonatology/obstetrics eliminated
- Transaction expected to be accretive to adjusted earnings growth on an annual basis
Financial Impact
$797M gross proceeds; $587M net cash; leverage reduction of 30bps; updated FY2026 revenue guidance $3.08B-$3.18B
Risk Factors
- Revenue base shrinks by ~$500M annually post-divestiture, reducing scale
- Execution risk in reinvesting proceeds into higher-growth surgical facilities
- Potential for further portfolio rationalization or M&A integration challenges
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | $23.32 | awaiting T+5 | — | $23.22 (−0.45%) |
Oct 26, 2026 1d ago | SC 13D/A | $19.47 | awaiting T+5 | — | $23.22 (+19.23%) |
Oct 26, 2026 1d ago | DEFA14A | $19.47 | awaiting T+5 | — | $23.22 (+19.23%) |
Oct 26, 2026 1d ago | 8-K | $19.47 | awaiting T+5 | — | $23.22 (+19.23%) |
Oct 13, 2026 13d ago | SC 13G | $14.83 $15.40 | ▲ +3.84% | ▲ +3.39% | $23.22 (+56.54%) |
Sep 17, 2026 5w ago | 8-K | $13.35 $14.20 | ▲ +6.37% | ▲ +5.77% | $23.22 (+73.90%) |
Sep 17, 2026 5w ago | Press Release | $13.35 $14.20 | ▲ +6.37% | ▲ +5.52% | $23.22 (+73.90%) |
Aug 20, 2026 9w ago | Insider Buy | $14.52 $13.69 | ▼ −5.72% | ▼ −6.19% | $23.22 (+59.88%) |
Aug 10, 2026 11w ago | 8-K | $15.95 $14.36 | ▼ −9.97% | ▼ −9.92% | $23.22 (+45.55%) |
Aug 10, 2026 11w ago | Press Release | $15.95 $14.36 | ▼ −9.97% | ▼ −9.92% | $23.22 (+45.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers